logo
Runner baffles doctors by curing his cancer without drugs or surgery - using an unconventional method

Runner baffles doctors by curing his cancer without drugs or surgery - using an unconventional method

Daily Mail​27-06-2025
A 103-year-old marathon runner claims he halted the spread of his cancer with a radical diet overhaul.
Mike Fremont, from Cincinnati, Ohio, went against doctors' advice and rejected drugs and surgery when he was diagnosed with stage 3 colon cancer at age 69.
Doctors at the Cleveland Clinic told him the disease would kill him within three months unless he began chemotherapy and radiotherapy, followed by surgery to remove the main tumor.
At that point, the cancer had already spread to his lymph nodes — a stage known as metastasis — when the disease is still potentially curable, but at high risk of becoming terminal.
Typically, doctors use drugs to shrink the tumor so it can be surgically removed.
But instead of opting for proven treatments, Fremont switched to a strict vegan diet centered on whole foods like sweet and white potatoes (without oil), tofu, leafy greens, legumes, vegetables, fruit, and non-dairy milks.
He claims the plant-based lifestyle cured his metastases. Two years later, he underwent surgery to remove the tumor and says he has been cancer-free ever since.
But doctors remain fiercely skeptical, warning that even the strictest vegan diet cannot replace chemotherapy or immunotherapy.
'While a healthy diet plays a supportive role in cancer care, doctors argue it must be combined with medical treatments. Nutrition alone cannot eliminate cancer.'
Cancer experts previously told the Daily Mail they are seeing a 'concerning' rise of patients using controversial treatments.
A 2023 study found 70 percent of cancer patients use alternative medicine, one in three of that share use it as their sole method of treatment and 27 percent hid it from their oncologists.
Dr Heber added: 'A nutritious diet should be used along with proper treatments in cancer patients, but diet alone absolutely cannot cure cancer.'
Around 75 percent of colorectal cancer patients will be alive five years after their diagnosis with treatment.
Without treatment, survival rates drop to just 44 percent after three years, making medical intervention absolutely crucial.
A former Yale University wrestler, Fremont had been an avid runner since the 70s when he was grieving the death of his wife.
His first of more than a dozen marathons was the 1972 Boston Marathon.
At 103, the retired engineer and climate activist still holds multiple world records as the fastest marathoner in the 88, 90, and 91-year-old age categories.
That's why it was so shocking when Fremont got the world-upending news in 1991.
He said: 'I contracted a cancer which the Cleveland Clinic said would kill me in 3 months unless operated upon.
'I said no, I was going on a diet!
'The tumor had metastasized into my lymphatic system and would have required efforts to treat the metastases with radiation and/or chemotherapy.'
Two years later he underwent an operation to remove the tumor from his colon when it began to bleed.
After the procedure, doctors checked for cancer spread in 35 places around Fremont's body, he said, and found zero signs of cancer spread to other parts of the body.
Fremont believes that his stellar health and advanced age are primarily due to his habits, rather than genetics. His father died of liver cancer, and his mother of a heart attack.
He said: 'The results of the diet have been perfect and it has been since that diet that all my world records have come about as well as such distinction in the US.'
And he doesn't plan on slowing down.
'My route is 5 miles long, through a scenic park near Cincinnati with mixed surface, lots of hills,' he said.
'The first mile is at my maximum speed, the other four under pressure to run fast. I resolved at age 98 to run 5 miles rather than 10, but to do it at speed.'
Fremont has always followed a disciplined fitness plan, saying he runs five miles three times a week and incorporating push-ups and pull-ups.
A typical day of eating for Fremont begins with oatmeal, syrup, and blueberries for breakfast.
Lunch consists of beans, while dinner includes broccoli florets topped with ketchup.
Fremont also lives a low-stress lifestyle, using exercise as a form of emotional release.
He also does not drink or smoke.
His healthy lifestyle has been shown to prevent cancer and its recurrence.
Research has shown that a structured exercise program for stage II and III colon cancer patients reduced recurrence by 28 percent, lowered mortality risk by 37 percent over eight years, and showed benefits with just 1.5 to 2.25 hours of brisk walking weekly.
Focusing on whole, unprocessed plant foods increases the amount of beneficial nutrients and compounds taken in that help reduce inflammation, a key factor in cancer development.
Additionally, these dietary choices can support healthy weight, cholesterol levels, and blood sugar control, all of which contribute to a lower cancer risk
But there is no concrete evidence diet alone can reverse cancer.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Viking's weight-loss pill data disappoints, shares sink
Viking's weight-loss pill data disappoints, shares sink

Reuters

time28 minutes ago

  • Reuters

Viking's weight-loss pill data disappoints, shares sink

Aug 19 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a mid-stage trial, missing Wall Street's top-end expectations of 15% and sending its shares plummeting by 41%. In the 280-person study of obese and overweight adults, those who received the highest 120-milligram dose of Viking's drug, VK2735, shed 12.2% of their body weight on average over 13 weeks versus 10.9% for those who received a placebo. However, about 20% of patients on VK2735 dropped out of the study due to adverse effects, primarily gastrointestinal issues such as vomiting and nausea, compared to 13% in the placebo group. The company will consider increasing it every four weeks for future studies, rather than every two weeks, to help control the side effects, Viking CEO Brian Lian said. Oral weight-loss drugs are expected to widen access for patients averse to injections, helping their makers tap into a projected $150 billion market currently dominated by Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound. But so far, oral pills have failed to outperform the injectables in the tight race for these medicines. Analysts expected Viking's drug to help lower body weight by 10% to 15%, following an 8.2% average reduction in an early-stage trial. J.P. Morgan analyst Hardik Parikh said the drug's profile did not measure up to earlier trials, but said side effects might be manageable with dose adjustments, particularly given the high discontinuation rate in the placebo group. Shares of Viking had gained 4.6% this year till Monday's close due to optimism over the obesity pill. In early August, Lilly's experimental daily pill, orforglipron, showed a 12.4% weight loss in a late-stage study over 72 weeks. The news wiped off more than $100 billion from the company's market value on the day. Separately, Novo's oral semaglutide has shown a weight-loss of 15% over 68 weeks. Both drugmakers expect to launch their oral drugs by next year.

US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder
US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder

Reuters

time28 minutes ago

  • Reuters

US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder

Aug 19 (Reuters) - The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' (PTCT.O), opens new tab oral medication for a rare genetic disorder with limited treatment options, the company said on Tuesday. In its so-called Complete Response Letter, the FDA said the data did not provide substantial efficacy evidence for the drug, vatiquinone, in treating Friedreich's ataxia and that a separate study was needed before resubmitting the application. At least three analysts said the regulator's rejection was not surprising and that expectations had been low heading into the decision. PTC's shares reversed premarket losses to rise more than 8% in morning trading. The FDA approved Sephience - PTC's oral therapy for a rare metabolic disorder called phenylketonuria - last month, potentially countering revenue declines due to regulatory scrutiny and competition from cheaper rivals for its top-selling muscular disorder therapies, Translarna and Emflaza. "We see today's CRL as a clearing event since investors can now turn their focus to the Sephience launch," analysts said in a client note. The company said it planned to meet with FDA officials to discuss potential next steps. "We are of course disappointed by the FDA's decision to not approve vatiquinone," CEO Matthew Klein said, adding that the data till date demonstrated that the drug could be safe and effective for children and adults living with the disorder. Friedreich's ataxia is a rare genetic disorder that causes progressive damage to the nervous system, often leading to difficulty in walking, speech problems and heart complications. The disease tends to develop in children and teenagers and gradually worsens over time. Vatiquinonedid not meet its main goal, opens new tab of significantly reducing disease progression in a key late-stage trial that was part of the company's marketing application. Currently, Biogen's (BIIB.O), opens new tab Skyclarys remains the only FDA-approved treatment for Friedreich's ataxia.

Action needed on plastic additives linked to sperm decline, experts warn
Action needed on plastic additives linked to sperm decline, experts warn

The Guardian

time41 minutes ago

  • The Guardian

Action needed on plastic additives linked to sperm decline, experts warn

Action must be taken to curb the use of plastic additives linked to plummeting sperm counts, a leading reproductive scientist has warned, as splits over chemical regulation contributed to the collapse of a crucial treaty on plastic pollution. Across the world, sperm counts have been declining at a rate of about 1% a year for the past 50 years, and human fertility has been diminishing at a similar rate, studies have shown. Increasing levels of obesity, sedentary lifestyles and ageing populations have all been held up as possible causes. But according to Dr Shanna Swan, professor of environmental medicine and public health at the Icahn School of Medicine at Mount Sinai in New York City, environmental factors play the most significant role. Swan said the decline was 'largely, but not entirely due to toxins in the environment that have the ability to interfere with steroid hormones'. In 2017, Swan and her colleagues published a meta-analysis showing a decline in sperm counts of almost 60% among men in North America, Europe and Australia between 1973 and 2011. In 2023, they repeated the research, extending the study to 2018 and including previously unavailable data from Africa, Asia and South America, and made even more shocking findings. 'We separated the countries into western and non-western for analytic purposes, and in both we found a significant decline,' Swan said. 'And the other thing that we found, which was at least as alarming, was that if you looked at all of the studies going back to 1973 you see a 1% per year decline. But if you look at studies published after 2000, you see an over 2% decline. 'So the rate of decline had increased, and had increased significantly in recent years.' Swan's warning comes amid rising alarm at the impact of chemical toxicity on human and environmental health. Two weeks ago, a report published by Deep Science Ventures, a business focused on environmental solutions, which was reviewed by Swan, warned that chemical pollution was 'a threat … of a similar order as climate change', but received far less attention. The decline in sperm rates since about 1950 stands in an inverse relationship to the explosion in the use of plastics. Swan points out that there are now well-established links between common additives to plastics and falling sperm counts. 'Phthalates are chemicals that are put into plastic to give it flexibility and make it soft and flexible,' Swan said. 'So anytime you pick up a soft water bottle or tubing, like medical tubing, or a food container that's soft, you're going to be touching phthalates. 'Then, on the other side, the evil twin of phthalates are the bisphenols. While phthalates make plastic soft and flexible, bisphenols make it hard and inflexible. And phthalates lower testosterone and the bisphenols increase oestrogen.' The effects of these and other endocrine-disrupting chemicals were particularly profound on foetuses and embryos developing in the womb, Swan said. She had previously carried out research into the effects of phthalates on unborn male babies, finding that exposure at a critical point in gestation could lead to subtle deformities in sexual development. Sign up to Down to Earth The planet's most important stories. Get all the week's environment news - the good, the bad and the essential after newsletter promotion The adverse effects of phthalates in the womb, known as 'phthalate syndrome', included smaller penises, a shorter distance between the genitals and anus, and – once children reached sexual maturity – lowered sperm counts, Swan said. 'We showed the link between the exposure and fertility,' she said. 'And when you see that total sperm count going down worldwide, what I believe is you're seeing an important effect of early exposure to these chemicals.' Swan would not be drawn into commenting on the talks, which were under way as she spoke, in Geneva for a comprehensive treaty to end the plastic pollution crisis. But she said action needed to be taken on the use of plastic additives, with an urgent need for safer replacements. 'In the meantime, yes people can be careful,' she said. 'They can reuse materials. They should try to look at what they use in their takeout containers and carry little glass bottles around to get their drinks. It's very important. But it's not solving a bigger problem, which is how do we make these things that we have become dependent on in a safer way?' Signs of a solution are not promising. Last week, after nearly two weeks of talks, negotiators left Geneva on Friday having failed to reach an agreement, after oil- and gas-producing nations objected to calls for limits to production and curbs on chemicals. Almost 100 nations had signed a declaration calling for a 'legally binding obligation to phase out those most harmful plastic products and chemicals of concern'. But both texts drafted by Luis Vayas Valdivieso, the chair of the negotiating committee, omitted any reference to controls on chemicals.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store